Literature DB >> 22917543

Management of bone tumours in paediatric oncology.

T Bölling1, J Hardes, U Dirksen.   

Abstract

The management of bone tumours in paediatric oncology requires careful multidisciplinary planning due to the need for multimodal therapy approaches. The non-specific symptoms often lead to a delayed definitive diagnosis of a bone tumour. Imaging procedures are of major importance for an individualised and optimised treatment planning. They have to be carried out before any surgery, including biopsies. The introduction of multi-agent chemotherapy has led to a significant improvement in survival rates in patients suffering from Ewing's sarcomas and osteosarcomas. However, local therapy still remains indispensable in order to achieve long-term survival. For osteosarcoma, surgery remains the only adequate local therapy modality. Radiotherapy may be considered if surgery is not feasible. In these cases, high radiation doses need to be applied. The choice for local therapy modality is not as clear in patients with Ewing's sarcoma. Today, surgery is often preferred if a wide or at least marginal resection can be carried out. Additional radiotherapy is advised in patients with marginal/intralesional resection or poor histological response to induction chemotherapy. Definitive radiotherapy is recommended for inoperable lesions. In the future, new radiotherapy approaches, such as intensity-modulated radiotherapy or proton therapy, may yield better results with minor risks of late effects.
Copyright © 2012 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22917543     DOI: 10.1016/j.clon.2012.07.010

Source DB:  PubMed          Journal:  Clin Oncol (R Coll Radiol)        ISSN: 0936-6555            Impact factor:   4.126


  7 in total

1.  Ewing's sarcoma of bone tumor cells produces MCSF that stimulates monocyte proliferation in a novel mouse model of Ewing's sarcoma of bone.

Authors:  B S Margulies; S D DeBoyace; T A Damron; M J Allen
Journal:  Bone       Date:  2015-06-05       Impact factor: 4.398

2.  Survival and recurrence rate after treatment for primary spinal sarcomas.

Authors:  Wonik Cho; Ung-Kyu Chang
Journal:  J Korean Neurosurg Soc       Date:  2013-04-30

Review 3.  Introducing fluorescence guided surgery into orthopedic oncology: A systematic review of candidate protein targets for Ewing sarcoma.

Authors:  Sarah E Bosma; Pieter Baa van Driel; Pancras Cw Hogendoorn; Pd Sander Dijkstra; Cornelis Fm Sier
Journal:  J Surg Oncol       Date:  2018-09-13       Impact factor: 3.454

4.  Identification of driver genes associated with chemotherapy resistance of Ewing's sarcoma.

Authors:  Hongyi Liao; Xianbiao Xie; Yuanyuan Xu; Gang Huang
Journal:  Onco Targets Ther       Date:  2018-10-15       Impact factor: 4.147

5.  LINGO-1 is a New Therapy Target and Biomarker for Ewing Sarcoma.

Authors:  Arvind Jain; Jing Zhang; Terence Rabbitts
Journal:  Clin Oncol (Belmont)       Date:  2017-01-05

6.  Massive FungatingEwing's Sarcoma of Scapula Treated by Limb Salvage Surgery: A Case Report.

Authors:  Pramod Chinder; Suraj Hindiskere; Srinath Doddarangappa; Utkarsh Pal; Kiran Tej Daggupati
Journal:  J Orthop Case Rep       Date:  2019 Jan-Feb

7.  Survival of children treated for Ewing sarcoma in Lithuania: a single centre experience.

Authors:  Gabrielius Jakutis; Lina Ragelienė; Jelena Rascon
Journal:  Acta Med Litu       Date:  2017
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.